A Belgian Registry of HUMIRA® (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis ( ProAct )

AbbVie

Status: Completed

Conditions: Psoriatic Arthritis; Ankylosing Spondylitis; Rheumatoid Arthritis

Study type: Observational

Funder types: Industry

Identifiers

NCT01078558

HUM04-28

Details and patient eligibility

About

This is a five year, post-marketing observational study to follow-up patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis who are treated with HUMIRA (adalimumab).

Enrollment: 5,940 patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with ongoing HUMIRA (adalimumab) treatment who have been prescribed HUMIRA (adalimumab) within local reimbursement guidelines.
• Patients must be willing to consent to data being collected and provided to Abbott Laboratories.

Exclusion criteria

• Contraindications according to the summary of product characteristics.
• Patients who are actually followed in the ReAlise registry (M03-634 NCT00234884).

Trial design

5,940 participants in 1 patient group

Patients with rheumatic disease

Description:

Patients suffering from rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis